What Vasogard Treats: Main Uses and Benefits

Vasogard (Cilostazol) is commonly used in situations involving certain distressing symptoms related to circulation. This medication is generally used to address Intermittent Claudication, a condition whose symptoms are often associated with Peripheral Arterial Disease (PAD). It is applied across domains where additional symptomatic support is needed. It is relevant for easing symptoms that interfere with daily functioning.

The therapeutic benefit focuses on the cramping, aching, or fatigue in the leg muscles that develops during physical activity. This supportive relief plays a role in managing symptoms that interfere with daily comfort and may become intense or disruptive during a walking episode. It assists with maintaining functional stability and contributes to easing the overall symptom load. It is commonly used across conditions presenting with episodic symptom patterns that limit activity.

---

Quick Fact: Relief for Activity-Limiting Leg Pain

Vasogard is applied in addressing symptoms related to physical discomfort in the lower limbs, which translates into an enhanced walking range. It assists with maintaining functional stability, making it possible to walk further distances before the onset of pain.

Regulatory References

1. NIH MedlinePlus Drug Information

Eligibility Rules for Vasogard (Cilostazol)

Official regulatory documents strictly define the population groups permitted and prohibited from using Vasogard (Cilostazol), focusing on pre-existing conditions and physiological status.

Populations Who Must Not Use Vasogard (Contraindications):

The medicine is absolutely contraindicated and must not be used by patients with heart failure of any severity, due to the drug’s pharmacological class. Use is also prohibited in individuals with a history of myocardial infarction or coronary intervention within the last six months, unstable angina, or certain severe tachyarrhythmias.

Vasogard is further contraindicated in patients with a high risk of bleeding, including active peptic ulceration or recent haemorrhagic stroke. Patients with moderate or severe hepatic impairment or severe renal impairment (creatinine clearance le 25 mL/min) are also excluded.

Special Population Status:

Status	Regulatory Classification
Pregnancy	Contraindicated (Must Not Be Used)
Breastfeeding	Not Recommended
Pediatrics	Safety and Efficacy Not Established

In adults, use is generally restricted to those symptomatic for Intermittent Claudication. The elderly are typically allowed with no special dosage requirements.

Interactions with other medicines and products

Official regulatory information addresses interactions that may alter the drug's concentration in the body or produce additive effects when co-administered with other substances.

Pharmacokinetic and Pharmacodynamic Interactions

Interaction Domain	Interacting Substance Categories	Practical Constraint
Exposure Alterations by Hepatic Modulators	Strong and moderate inhibitors of CYP3A4 (e.g., Itraconazole)	Co-administration may significantly increase drug levels, requiring close monitoring or use of an alternative medicine.
Exposure Alterations by Hepatic Modulators	Inducers of CYP3A4 (e.g., Rifampin, Carbamazepine, Dexamethasone, Enzalutamide)	Co-administration may reduce the desired effect of the drug, necessitating frequent monitoring of blood pressure or dose adjustments.
Additive Pharmacological Effects	Other anti-hypertensive agents	Caution is advised due to the risk of excessive lowering of blood pressure.
Additive Pharmacological Effects	Dantrolene	Co-administration may increase the risk of hyperkalemia.

Food, Alcohol, and Substance Interactions

Consumption of Grapefruit Juice is not recommended as it may increase the concentration of the drug in the body. Alcohol consumption is advised with caution, especially upon starting treatment or when the dosage is being adjusted, due to potential effects like dizziness.

Population-Specific Constraints

Caution is recommended for patients with hepatic impairment due to the drug’s metabolism in the liver. A lower starting dose and slow, careful increase with close monitoring is a required procedural constraint in these patients, reflecting their reduced capacity to handle potential changes in drug exposure.

Vasogard (Cilostazol) exerts a dual mechanism that targets the enzyme system regulating both blood vessel tension and platelet activity, influencing hemodynamics in the peripheral circulatory system.

Core Action: Selective Phosphodiesterase III (PDE3) Inhibition

The drug acts as a selective inhibitor of the PDE3 enzyme, which is responsible for hydrolyzing the intracellular signaling molecule, cyclic adenosine monophosphate (cAMP). By blocking PDE3, Cilostazol prevents the breakdown of cAMP, leading to elevated intracellular cAMP levels within target cells. This molecular step initiates the drug's physiological cascade, as increased cAMP acts as a critical messenger to modulate both vascular smooth muscle tone and platelet activity.

Dual Cascade: Vasodilation and Antiplatelet Activity

The elevated cAMP activates a cascade that results in two simultaneous physiological consequences: Arterial Vasodilation and Reduced Platelet Aggregation. Within vascular smooth muscle cells, the rise in cAMP causes the muscles to relax, leading to the widening of peripheral arteries and a decrease in vascular resistance. Concurrently, in platelets, the same signal inhibits the processes that cause them to aggregate, thereby reducing the blood's viscosity and tendency toward clump formation. The combination of these actions influences vascular resistance and blood viscosity, affecting systemic perfusion.

How to Use Vasogard

The usage of Vasogard (Cilostazol) follows specific instructions regarding dose, frequency, and relationship to food. The medicine is consistently administered via the oral route in the available 50 mg and 100 mg tablet strengths.

Administration Parameter	Instruction
Standard Dosing	100 mg administered twice daily.
Timing Constraint	Must be taken either 30 minutes before or 2 hours after both breakfast and dinner to manage systemic exposure.
Dose Adjustment	Dose is reduced to 50 mg twice daily when certain strong or moderate CYP3A4 or CYP2C19 inhibitors (e.g., omeprazole, diltiazem) are co-administered.

---

Course Duration and Assessment

The use of Cilostazol follows a defined period for therapeutic evaluation. Therapy is typically maintained for up to 12 weeks to allow for the full expression of its intended effect. The protocol involves discontinuation if symptomatic improvement is not observed after this three-month assessment period.

Use in Specific Populations

No specific dosage adjustment is required for older adults. Similarly, the standard regimen applies to patients with mild hepatic impairment or renal impairment where creatinine clearance is greater than 25 mL/min. The overall use protocol is standardized across these groups unless specific enzyme inhibitor co-medications necessitate the reduced 50 mg dose.

Research Evidence / Overview of Studies for Vasogard (Cilostazol)

---

Evidence for Use in Intermittent Claudication (IC)

The core research exploring this medicine was studied for intermittent claudication (IC) primarily consisted of randomized, double-blind, placebo-controlled trials (DB-PCTs), which are essential for evaluating changes in outcomes. These studies primarily focused on populations of adults diagnosed with stable intermittent claudication due to Peripheral Arterial Disease (PAD). Researchers used standardized treadmill tests to measure outcomes reflecting daily functioning or activity level, specifically tracking the Pain-Free Walking Distance (PFWD) and the Maximum Walking Distance (MWD).

The studies describe patterns observed in the participants' walking ability when compared to a placebo pill. Studies reported measurements of distance over the observed period, and the research described patterns where walking distances evolved in the study populations. Evidence contributes to understanding symptom patterns over defined time intervals, most commonly over periods of 12 to 24 weeks.

What remains uncertain is the long-term functional durability of these changes, as the data relating to changes measured in functional capacity often relates to the short-term timeframe. Evidence is limited regarding the association between the drug and definitive, long-term clinical events, such as the rate of revascularization or major cardiovascular events.

---

Evidence for Use in Secondary Stroke Prevention

Research has also examined the drug's role in secondary prevention in patients who have recently experienced a noncardioembolic ischemic stroke or a high-risk transient ischemic attack (TIA). This evidence is largely derived from randomized controlled trials and meta-analyses, often studying the drug in combination with other antiplatelet agents.

The studies examined outcomes describing episodic or acute changes, focusing on the rates of recurrent ischemic stroke and other major adverse cardiovascular events (MACE). Studies report how symptoms evolved in the observed populations and findings indicate patterns related to the rate of recurrence over the long-term (e.g., beyond 3 months).

A key limitation of this evidence is its geographical focus. The bulk of the research was conducted in East Asian populations, and certainty remains low regarding the direct applicability of these results to other ethnic groups. Data are still emerging regarding the drug’s potential association with long-term functional recovery or cognitive changes.

Key Studies & References

1. Label: CILOSTAZOL tablet - DailyMed - NIH (Regulatory/Safety Information)
2. Systematic review and meta-analysis of randomized clinical trials appraising the impact of cilostazol after percutaneous coronary intervention (PCI Restenosis/TLR)

Common questions about Vasogard (FAQ)

Q: What official information is provided about what to do after missing a dose of Vasogard?

Official instructions state that a missed dose may be taken as soon as remembered. However, if it is close to the time of the next scheduled dose, regulatory information indicates that the missed dose should be skipped. Regulatory guidance strictly advises against taking a double dose to make up for the one that was missed.

---

Q: Is Vasogard available as a generic medicine?

Vasogard is the brand name for the active chemical compound, Cilostazol. Official regulatory data confirms that Cilostazol is also widely available as a generic medicine.

---

Q: How is Vasogard different from other medications used for the same purpose?

Vasogard is classified by regulators as a selective Phosphodiesterase III (PDE3) inhibitor. This classification indicates the drug has a dual action: it works by promoting vasodilation (widening of blood vessels) and reducing platelet aggregation (blood clotting) simultaneously.

---

Q: What types of foods or drinks, if any, are listed as potentially interacting with Vasogard?

Regulatory information advises caution or avoidance regarding the consumption of grapefruit and grapefruit juice while using Vasogard. Official documents indicate that consuming these items may increase the concentration of the drug within the body.

---

Q: Is there any official information about Vasogard interacting with alcohol?

Official product information notes that caution is advised regarding alcohol consumption, especially when first starting treatment with Vasogard. This is provided because alcohol may increase the risk of experiencing dizziness, which is a very common side effect of the medicine.

---

Q: What happens if a patient stops taking Vasogard suddenly?

Research evidence indicates that the beneficial effects of Vasogard on walking ability, particularly the documented patterns of improvement, may be lost after abrupt discontinuation of the treatment.

---

Q: Is it common to experience headache or dizziness when first starting Vasogard?

Headache and dizziness are listed in regulatory documents as very common adverse reactions, meaning they affect one in ten individuals or more. Studies examining these effects suggest that the majority of adverse reactions reported typically occur within the first month of starting treatment.

---

Q: Is Vasogard considered a first-line treatment for the condition it addresses?

Vasogard is an FDA-approved treatment intended to address intermittent claudication. Regulatory guidance references its therapeutic trial alongside other treatments, such as risk factor modification.

---

Q: What are the main findings or themes from the clinical research evidence on Vasogard?

Clinical research describes patterns of improvement in walking distance for patients with intermittent claudication. Specifically, evidence indicates increases in both the pain-free walking distance and the maximum walking distance when compared to placebo groups over the study periods.

---

Q: What is the general expectation for ongoing health monitoring while using Vasogard?

Regulatory information advises that close monitoring is expected for patients, particularly for signs of bleeding or bruising due to the drug’s antiplatelet action. Monitoring may also involve observation for symptoms that could suggest the early development of blood dyscrasias, which might require further evaluation.

---

Q: Can Vasogard be taken alongside daily vitamins or mineral supplements?

Official prescribing information consistently states that patients should inform the prescribing doctor and pharmacist about all prescription and nonprescription medications. This includes any vitamins, nutritional supplements, and herbal products that are currently being taken.

---

Q: What information is available regarding Vasogard use in the elderly population?

Pharmacokinetic studies examining the clearance of the drug showed that it was not significantly different in older adults, specifically those aged 50 to 80 years. This indicates that standard use protocols generally apply to the elderly population.

---

Q: Is Vasogard known to cause muscle aches or weakness?

According to regulatory documents, muscle pain is listed as a possible side effect of Vasogard. This is included in the official safety profile for the medicine.

---

Q: Does Vasogard affect blood sugar levels or is it safe for people with diabetes?

Clinical studies that examined the drug's effect on patients with diabetes mellitus found no significant differences in fasting blood glucose or HbA1c levels between treatment groups and placebo over the study period.

---

Q: Are there different strengths of Vasogard tablets available?

Regulatory documents, such as the FDA labeling, confirm that the medicine is officially available in two tablet strengths. These available strengths are 50 mg and 100 mg.

---

Q: Is there any evidence that Vasogard can cause changes in mood or sleep patterns?

Some clinical study reports mention insomnia, which is a sleep disorder, as an adverse event experienced by patients using the drug. Changes in sleep patterns are documented within the adverse event reporting system.

---

Q: Does Vasogard contain any ingredients that could trigger known allergies?

Official labeling states that Vasogard must not be used if a patient is allergic to the active ingredient, Cilostazol, or any of the other non-active ingredients (excipients).

---

Q: Are there any specific lifestyle changes recommended when starting Vasogard?

Official information states that patients are advised not to smoke tobacco while taking the medicine. This is because smoking has been shown to potentially decrease the drug’s exposure in the body.

---

Q: Are there any specific population groups where the safety of Vasogard has been studied less?

Regulatory summaries for trials concerning stroke prevention note that the majority of research was conducted in East Asian populations. Consequently, certainty remains low regarding the direct applicability of these results to other ethnic groups.

How to Store and Dispose of Vasogard (Cilostazol)

Vasogard tablets must be stored and handled strictly according to the conditions defined in regulatory labeling to maintain stability and ensure safety.

---

Storage Requirements

Vasogard must be stored at controlled room temperature, specifically 20 C to 25 C (68 F to 77 F), with permitted excursions up to 30 C. The medicine must be kept in its original container, tightly closed, and protected from both moisture and freezing.

It is mandatory to store the medication out of the sight and reach of children.

---

Disposal Instructions

Unused or expired Vasogard must be discarded following specific local regulatory requirements. The product must not be thrown away via household trash or wastewater to prevent environmental contamination. Patients are instructed to consult a pharmacist for guidance on proper disposal.